AA
NDRM

ALPS Advisors’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

ALPS Advisors’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,936
Closed -$1.01M – 912
2017
Q3 		$1.01M Buy
25,936
+2,165
+9% +$79.6K 0.01% 240
2017
Q2 		$711K Buy
23,771
+1,114
+5% +$28.9K 0.01% 289
2017
Q1 		$587K Buy
22,657
+1,891
+9% +$46.8K ﹤0.01% 289
2016
Q4 		$461K Sell
20,766
-6,832
-25% -$128K ﹤0.01% 480
2016
Q3 		$510K Sell
27,598
-2,814
-9% -$48.8K ﹤0.01% 267
2016
Q2 		$494K Buy
30,412
+6,192
+26% +$104K ﹤0.01% 276
2016
Q1 		$342K Sell
24,220
-4,152
-15% -$56.1K ﹤0.01% 577
2015
Q4 		$484K Sell
28,372
-5,315
-16% -$104K ﹤0.01% 488
2015
Q3 		$6.96K Buy
33,687
+16,814
+100% +$345K 0.01% 232
2015
Q2 		$259K Buy
+16,873
New +$237K ﹤0.01% 665

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

ALPS Advisors's NDRM Position: Q4 2017 in Review

ALPS Advisors sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 25,936 shares — an estimated $1.01M sold.

ALPS Advisors first reported a position in NDRM in Q2 2015 and held it in 10 quarters. The position peaked at $1.01M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • ALPS Advisors reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • ALPS Advisors sold 25,936 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $1.01M.
  • ALPS Advisors first reported a position in NeuroDerm Ltd. Ordinary Shares in Q2 2015 and held it in 10 quarters.
  • ALPS Advisors's NeuroDerm Ltd. Ordinary Shares position peaked at $1.01M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on ALPS Advisors's 13F filing for Q4 2017, filed 5 Feb 2018.